Review Article
Ewing's Sarcoma: Development of RNA Interference-Based Therapy for Advanced Disease
Table 1
RNAi drugs in human clinical trials [
113–
115].
| Company | Product name | Disease | Target | Stage |
| Alnylam | ALN-RSV1 | Respratory syncytial virus infection | Nucleocapsid (N) gene of RSV genome | Expanded phase II | Alnylam | ALN-VSP | Liver cancers and solid tumors | Kinesin spindle protein (KSP), VEGF | Phase I | Alnylam | ALN-TTR01 | TTR-mediated amyloidosis | TTR | Phase I | Alnylam | ALN-PCS | hypercholesterolemia | PCSK9 | Phase I | Benetec/City of Hope | — | AIDS lymphoma | rHIV7-shI-TAR-CCR5RZ | Phase I | Calando Pharmaceuticals | CALAA-01 | Cancer and solid tumors | M2 subunit of ribonucleotide reductase (RRM2) | Phase I | Cequent Pharmaceuticals | CEQ508 | FAP | β-Catenin | Phase I | Duke University | — | Metastatic melanoma | LMP2, LMP7, and MECL1 | Phase I | OPKO Health | Bevasiranib | Wet age-related macular degeneration | VEGF | Expanded phase III | OPKO Health | Bevasiranib | Diabetic macular edema | VEGF | Phase II | Quark Pharmaceuticals | PF4523655/RTP801i14 | Wet age-related macular degeneration | RTP801 | Phase II | Quark Pharmaceuticals | PF4523655/RTP801i14 | Diabetic macular edema | RTP801 | Phase II | Quark Pharmaceuticals | QPI-1002/Akli5/I5NP | Acute kidney injury | P53 | Phase I/IIa | Quark Pharmaceuticals | QPI-1002/DGFi | Delayed graft function in kidney transplantation | P53 | Phase I/II | Sirna Therapeutics (MERCK)/Allergan | Sirna-027/AGN-745 | Wet age-related macular degeneration | VEGFRI | Phase II | Silence Therapeutics | Atu027 | Lung cancers | Protein kinase N3 (PKN3) | Phase I | SENETEK | — | Brain tumors glioblastomas | Tenascin-C | Phase I | Tekmira | ApoB SNALP | High LDL cholesterol | Apo B lipoprotein | Phase I/II | Tekmira | TKM-PLK1 | Advanced solid tumor | PLK1 | Phase I | TransDerm, Inc | TD101 | Pachyonichia congenita | Keratin 6a (K6a) | Phase I | University of Duisbur-Essen | — | Chronic myeloid leukaemia | bcr-abl | Single patient | Gradalis, Inc. | FANG | Advanced cancer | Furin | Phase I | Gradalis, Inc. | FANG | Ovarian | Furin | Phase II | Gradalis, Inc. | FANG | Melanoma | Furin | Phase II | Gradalis, Inc. | FANG | Colon cancer | Furin | Phase II |
|
|